MaxCyte reports preliminary FY2025 core revenue in-line with guidance

MAXCYTE, INC.

2025-FY EPS reported -$0.42 vs consensus -$0.08 ▼ miss (-414.7%)

Core revenue Q4 2025 est. $6.6-6.7M; full year $29.5-29.6M.
SPL program-related revenue Q4 $0.4-0.6M; full year $3.3-3.5M.
Cash, equivalents & investments ~$155.6M at Dec 31, 2025.
CEO cites challenging year, cost restructuring, expects revenue growth in H2 2026.
Preliminary unaudited results; audited FY2025 results due March 2026.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.